InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
59,703.47
(
0.79%
)
Post# of 45886
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

QuicKtip

Send PM Follow Ignore
Followers 17
Posts 3878
Boards Moderated 2
Alias Born 08/23/2022

QuicKtip

Re: None

Thursday, 10/05/2023 1:02:17 PM

Thursday, October 05, 2023 1:02:17 PM

Post# of 45886
This little-known NASDAQ carries a $21 price target and its CEO is buying up shares…

Atai Life Sciences (NASDAQ: ATAI)

The company has plenty of cash on hand to the tune of $227M as reported in the company’s last financial report. AND… the company has anticipated runway all the way into the first half of 2026!

First major collaboration between this type of biotech and a big pharma company!

ATAI currently has 8 clinical stage development programs with a focus on compound classes with prior evidence in humans; a portfolio approach to avoid binary risk and optimize the likelihood of success.

Read more in the FULL REPORT

https://broadstreetalerts.com/wp-content/uploads/2023/10/ATAI-Full-Report-BSA.pdf
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up